Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

SARS-CoV-2 rS

Vaccine (Recombinant protein vaccine) · Immune activation, directed at SARS-CoV-2 spike protein · developed by Novavax

Phase 1/2 Most advanced trial (none active)
NVAX Developer
1 Registered trials

What is SARS-CoV-2 rS?

SARS-CoV-2 rS is a recombinant spike protein vaccine administered as intramuscular injections. It is studied in COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine (Recombinant protein vaccine)
Targets
SARS-CoV-2 spike protein (antigen)
Mechanism
Immune activation, directed at SARS-CoV-2 spike protein
Pathways
immune_activation
Therapy area
Infectious disease
Developer
Novavax (NVAX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04368988 Phase 1/2 COVID-19 Completed NVAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19

More from Novavax

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the NVAX page.

Follow NVAX, the company behind SARS-CoV-2 rS

See NVAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVAX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.